Correlation Between GlaxoSmithKline PLC and DBS Group

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and DBS Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and DBS Group into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and DBS Group Holdings, you can compare the effects of market volatilities on GlaxoSmithKline PLC and DBS Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of DBS Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and DBS Group.

Diversification Opportunities for GlaxoSmithKline PLC and DBS Group

-0.67
  Correlation Coefficient

Excellent diversification

The 3 months correlation between GlaxoSmithKline and DBS is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and DBS Group Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DBS Group Holdings and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with DBS Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DBS Group Holdings has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and DBS Group go up and down completely randomly.

Pair Corralation between GlaxoSmithKline PLC and DBS Group

Considering the 90-day investment horizon GlaxoSmithKline PLC is expected to generate 9.38 times less return on investment than DBS Group. But when comparing it to its historical volatility, GlaxoSmithKline PLC ADR is 2.25 times less risky than DBS Group. It trades about 0.01 of its potential returns per unit of risk. DBS Group Holdings is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  1,937  in DBS Group Holdings on August 30, 2024 and sell it today you would earn a total of  1,149  from holding DBS Group Holdings or generate 59.32% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

GlaxoSmithKline PLC ADR  vs.  DBS Group Holdings

 Performance 
       Timeline  
GlaxoSmithKline PLC ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GlaxoSmithKline PLC ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
DBS Group Holdings 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in DBS Group Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental indicators, DBS Group may actually be approaching a critical reversion point that can send shares even higher in December 2024.

GlaxoSmithKline PLC and DBS Group Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GlaxoSmithKline PLC and DBS Group

The main advantage of trading using opposite GlaxoSmithKline PLC and DBS Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, DBS Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBS Group will offset losses from the drop in DBS Group's long position.
The idea behind GlaxoSmithKline PLC ADR and DBS Group Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Complementary Tools

Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world
Commodity Directory
Find actively traded commodities issued by global exchanges